Hui-Zi Chen, MD, PhD

Publications

• Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8-DNA interactions and effectively inhibits prostate tumor growth in mice.

  (Karan D, Dubey S, Gunewardena S, Iczkowski KA, Singh M, Liu P, Poletti A, Choo YM, Chen HZ, Hamann MT.) Mol Oncol. 2024 Aug;18(8):1966-1979 PMID: 38605607 PMCID: PMC11306517 SCOPUS ID: 2-s2.0-85190504464 04/12/2024

• ALK fusions in the pan-cancer setting: another tumor-agnostic target?

  (Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R.) NPJ Precis Oncol. 2023 Sep 29;7(1):101 PMID: 37773318 PMCID: PMC10542332 SCOPUS ID: 2-s2.0-85173930134 09/29/2023

• Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.

  (Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich PP, Hampel H.) Fam Cancer. 2023 Jan;22(1):91-97 PMID: 35713757 PMCID: PMC9204376 06/18/2022

• Effectiveness of a novel 1% glucose isotonic electrolyte solution for intraoperative fluid therapy in children: a randomized controlled trial.

  (Gao ZZ, Wang F, Hua L, Cui XH, Xu J, Fu WY, Chen HZ.) J Int Med Res. 2021 Nov;49(11):3000605211055624 PMID: 34775865 PMCID: PMC8593312 11/16/2021

• Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer.

  (Miller ED, Nalin AP, Diaz Pardo DA, Arnett AL, Huang E, Gasior AC, Malalur P, Chen HZ, Williams TM, Bazan JG.) J Natl Compr Canc Netw. 2021 Jun 10;20(6):644-652.e2 PMID: 34111839 06/11/2021

• Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy.

  (Chen HZ, Bonneville R, Paruchuri A, Reeser JW, Wing MR, Samorodnitsky E, Krook MA, Smith AM, Dao T, Miya J, Wang W, Yu L, Freud AG, Allenby P, Cole S, Otterson G, Shields P, Carbone DP, Roychowdhury S.) JTO Clin Res Rep. 2021 Apr;2(4):100164 PMID: 34590014 PMCID: PMC8474405 10/01/2021

• Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.

  (Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S.) Br J Cancer. 2021 Mar;124(5):880-892 PMID: 33268819 PMCID: PMC7921129 12/04/2020

• Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing.

  (Bonneville R, Paruchuri A, Wing MR, Krook MA, Reeser JW, Chen HZ, Dao T, Samorodnitsky E, Smith AM, Yu L, Nowacki N, Chen W, Roychowdhury S.) Mol Cancer Res. 2021 Mar;19(3):465-474 PMID: 33229401 PMCID: PMC7939074 11/25/2020

• Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.

  (Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S.) Mol Cancer Ther. 2020 Mar;19(3):847-857 PMID: 31911531 PMCID: PMC7359896 01/09/2020

• Research Autopsy Demonstrates Polyclonal Acquired Resistance in a Patient With Metastatic GI Stromal Tumor.

  (Paruchuri A, Chen HZ, Bonneville R, Reeser JW, Wing MR, Krook MA, Samorodnitsky E, Miya J, Dao T, Smith A, Freud AG, Allenby P, Roychowdhury S.) JCO Precis Oncol. 2020;4 PMID: 32923900 PMCID: PMC7446505 09/15/2020

• Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing.

  (Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S.) Methods Mol Biol. 2020;2055:119-132 PMID: 31502149 PMCID: PMC7010320 09/11/2019

• Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

  (Krook MA, Bonneville R, Chen HZ, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, Freud AG, Allenby P, Roychowdhury S.) Cold Spring Harb Mol Case Stud. 2019 Aug;5(4) PMID: 31371345 PMCID: PMC6672025 08/03/2019